Kunle Odunsi, MD, PhD, FRCOG, FACOG

home / authors / kunle-odunsi-md-phd-frcog-facog

Articles

Proposed Trial Would Be First Ever for Novel Two-Pronged Immunotherapy Strategy

Proposed Trial Would Be First Ever for Novel Two-Pronged Immunotherapy Strategy

Kunle Odunsi, MD, PhD, FRCOG, FACOG
November 13th 2015

Roswell Park Cancer Institute is taking the final steps toward what we believe would be the first-ever clinical trial combining two novel and highly promising techniques: adoptive cellular therapy utilizing re-engineered mature T cells and re-engineered adult hematopoietic stem cells.

Read More

Latest Updated Articles

Brigatinib in NF2-Related Schwannomatosis with Progressive Tumors
Published: August 22nd 2024 | Updated: August 29th 2024
Brigatinib in NF2-Related Schwannomatosis with Progressive Tumors
Long-term Follow-up of Selinexor Maintenance for Patients With TP53wt Advanced or Recurrent Endometrial Cancer: A Prespecified Subgroup Analysis From the Phase 3 ENGOT-EN5/GOG-3055/SIENDO Study
Published: August 6th 2024 | Updated: August 19th 2024
Long-term Follow-up of Selinexor Maintenance for Patients With TP53wt Advanced or Recurrent Endometrial Cancer: A Prespecified Subgroup Analysis From the Phase 3 ENGOT-EN5/GOG-3055/SIENDO Study
Sarwish Rafiq, PhD
Published: July 9th 2024 | Updated: July 10th 2024
Dr Rafiq on Novel Strategies for CAR T-Cell Engineering in Solid Tumors
Jens Hoeppner, FAChirg, FACS, MD
Published: June 2nd 2024 | Updated: June 3rd 2024
Perioperative Chemotherapy Prolongs OS vs Neoadjuvant Chemoradiation in Esophageal Cancer
Caroline Robert, MD, PhD
Published: September 15th 2024 | Updated: September 18th 2024
Long-Term KEYNOTE-006 Data Support Pembrolizumab as SOC in Advanced Melanoma
Sameh Gaballa, MD
Published: August 19th 2024 | Updated: September 18th 2024
Case Studies: Three follicular lymphoma cases treated with oral tazemetostat